NCT00658697 - Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

September 30, 2014

Study Completion Date

June 30, 2015

Conditions

Prostate Cancer

Interventions

DRUG

Docetaxel

Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles

DRUG

Bevacizumab

Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles

DRUG

ADT

Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)

DRUG

Bicalutamide

Starting on day 84 orally once daily until hormone therapy is completed

Trial Locations (3)

University of Maryland - Greenebaum Cancer Center, Baltimore

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston